Stephanie K. Tankou

Neurology
5 E 98th St
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein.

Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein.

Journal: bioRxiv : the preprint server for biology
Published: January 27, 2025

Oral vancomycin treatment alters levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAE.

Oral vancomycin treatment alters levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAE.

Journal: Brain, behavior, and immunity
Published: June 14, 2024

Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE.

Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE.

Journal: iScience
Published: April 18, 2023

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 28, 2022

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.

Journal: Multiple sclerosis and related disorders
Published: July 22, 2022

Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis.

Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis.

Journal: Microbiome
Published: July 08, 2022

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.

Journal: medRxiv : the preprint server for health sciences
Published: June 23, 2022

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.

Journal: Multiple sclerosis and related disorders
Published: November 11, 2021

Gut Microbiome in Progressive Multiple Sclerosis.

Gut Microbiome in Progressive Multiple Sclerosis.

Journal: Annals of neurology
Published: October 05, 2020

Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila.

Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila.

Journal: Cell host & microbe
Published: April 03, 2019

Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors.

Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors.

Journal: Scientific reports
Published: March 15, 2019

Investigation of probiotics in multiple sclerosis.

Investigation of probiotics in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 09, 2018
Showing 1-12 of 15

Last Updated: 09/26/2026